Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) were up 6.7% on Wednesday . The company traded as high as $12.09 and last traded at $12.14. Approximately 83,431 shares were traded during trading, a decline of 82% from the average daily volume of 471,568 shares. The stock had previously closed at $11.37.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $40.50.
Check Out Our Latest Report on Pliant Therapeutics
Pliant Therapeutics Stock Down 34.8 %
The stock has a market capitalization of $474.02 million, a price-to-earnings ratio of -2.33 and a beta of 1.03. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The business's 50-day moving average is $12.67 and its two-hundred day moving average is $12.94.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.04. Equities analysts anticipate that Pliant Therapeutics, Inc. will post -3.65 EPS for the current year.
Insider Activity
In related news, CEO Bernard Coulie sold 52,419 shares of Pliant Therapeutics stock in a transaction on Friday, January 17th. The stock was sold at an average price of $11.20, for a total value of $587,092.80. Following the completion of the transaction, the chief executive officer now directly owns 430,517 shares in the company, valued at approximately $4,821,790.40. This trade represents a 10.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Hans Hull sold 15,936 shares of Pliant Therapeutics stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the transaction, the insider now owns 211,558 shares of the company's stock, valued at $2,369,449.60. The trade was a 7.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,855 shares of company stock valued at $1,026,628 in the last quarter. Insiders own 6.40% of the company's stock.
Hedge Funds Weigh In On Pliant Therapeutics
Large investors have recently bought and sold shares of the business. Candriam S.C.A. increased its holdings in shares of Pliant Therapeutics by 8.0% in the 4th quarter. Candriam S.C.A. now owns 900,104 shares of the company's stock valued at $11,854,000 after acquiring an additional 66,888 shares during the last quarter. Atria Investments Inc boosted its holdings in Pliant Therapeutics by 18.1% in the fourth quarter. Atria Investments Inc now owns 11,821 shares of the company's stock valued at $156,000 after purchasing an additional 1,812 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pliant Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock valued at $6,050,000 after purchasing an additional 2,721 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in Pliant Therapeutics by 2.1% during the fourth quarter. Rice Hall James & Associates LLC now owns 160,522 shares of the company's stock worth $2,114,000 after purchasing an additional 3,305 shares in the last quarter. Finally, HighMark Wealth Management LLC lifted its position in shares of Pliant Therapeutics by 11.1% during the 4th quarter. HighMark Wealth Management LLC now owns 75,000 shares of the company's stock worth $988,000 after buying an additional 7,500 shares during the last quarter. Hedge funds and other institutional investors own 97.30% of the company's stock.
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Further Reading
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
